Table 2.

Clinical characteristics of the prostate cancer disease in men without or with the MetS as per NCEP and IDF definitions

No MetS NCEP definitionMetS NCEP definitionNo MetS IDF definitionMetS IDF definitionAll PC
Age, median (range)73 (51-83)74 (60-81)73 (51-83)72 (60-81)73 (51-83)
Method of diagnosis, n (%)
    Histology159 (81.5)25 (80.6)162 (80.2)26 (81.2)190 (80.2)
    Cytology27 (13.8)4 (12.9)30 (14.9)3 (9.4)34 (14.3)
    Clinical2 (1.0)0 (0.0)4 (2.0)0 (0.0)4 (1.7)
    Missing7 (3.6)2 (6.5)6 (3.0)3 (9.4)9 (3.8)
Method of detection, n (%)
    PSA screening3 (1.5)0 (0.0)3 (1.5)0 (0.0)3 (1.3)
    Incidentally discovered*12 (6.2)3 (9.7)15 (7.4)1 (3.1)16 (6.8)
    Other urological/skeletal symptoms7 (3.6)1 (3.2)7 (3.5)1 (3.1)8 (3.4)
    LUTS119 (61.0)16 (51.6)120 (59.4)21 (65.6)143 (60.3)
    Other symptoms29 (14.9)6 (19.4)31 (15.3)5 (15.6)37 (15.6)
    Missing25 (12.8)5 (16.1)26 (12.9)4 (12.5)30 (12.7)
PSA level, n (%)
    ≤47 (3.6)1 (3.2)7 (3.5)1 (3.1)8 (3.4)
    4.01-10.027 (13.8)2 (6.5)28 (13.9)2 (6.2)31 (13.1)
    10.01-20.028 (14.4)5 (16.1)33 (16.3)1 (3.1)34 (14.3)
    20.01-100.037 (19.0)5 (16.1)38 (18.8)8 (25.0)47 (19.8)
    >10018 (9.2)6 (19.4)20 (9.9)5 (15.6)25 (10.5)
    Missing78 (40.0)12 (38.7)76 (37.6)15 (46.9)92 (38.8)
Tumor stage, n (%)
    T0/T1ab25 (12.8)7 (22.6)27 (13.4)6 (18.8)34 (14.3)
    T1c24 (12.3)2 (6.5)25 (12.4)3 (9.4)28 (11.8)
    T274 (37.9)15 (48.4)79 (39.1)15 (46.9)96 (40.5)
    T3-451 (26.2)5 (16.1)51 (25.2)5 (15.6)56 (23.6)
    TX/missing21 (10.8)2 (6.5)20 (9.9)3 (9.4)23 (9.7)
N stage, n (%)
    N029 (14.9)5 (16.1)31 (15.3)4 (12.5)35 (14.8)
    N112 (6.2)0 (0.0)10 (5.0)1 (3.1)12 (5.1)
    NX132 (67.7)25 (80.6)140 (69.3)24 (75.0)166 (70.0)
    Missing22 (11.3)1 (3.2)21 (10.4)3 (9.4)24 (10.1)
M stage, n (%)
    M081 (41.5)13 (41.9)80 (39.6)18 (56.2)99 (41.8)
    MX, PSA ≤2010 (5.1)1 (3.2)11 (5.4)1 (3.1)12 (5.1)
    MX, 20<PSA≤10027 (13.8)5 (16.1)31 (15.3)2 (6.2)34 (14.3)
    M1/PSA>10044 (22.6)8 (25.8)46 (22.8)6 (18.8)53 (22.4)
    Missing33 (16.9)4 (12.9)34 (16.8)5 (15.6)39 (16.5)
Gleason score§, n (%)
    2-676 (39.0)10 (32.3)77 (38.1)12 (37.5)90 (38.0)
    748 (24.6)8 (25.8)50 (24.8)8 (25.0)59 (24.9)
    8-1051 (26.2)11 (35.5)55 (27.2)8 (25.0)64 (27.0)
    Missing20 (10.3)2 (6.5)20 (9.9)4 (12.5)24 (10.1)
  • *Incidentally discovered under investigation for symptoms not related to the urinary tract.

  • Lower urinary tract symptoms.

  • As classified by the International Union Against Cancer.

  • §WHO grade translated into Gleason score G1 (2-6), G2 (7), G3 (8-10).